Calithera Biosciences, Inc. CALA
We take great care to ensure that the data presented and summarized in this overview for Calithera Biosciences, Inc. is accurate and up-to-date, based on a comprehensive analysis of 13F filing forms for institutional ownership and form 4 filings for insider transactions. Please note that this data may differ from other sources and should not be relied upon as the sole basis for investment decisions.
Latest Institutional Activity in CALA
Top Purchases
Top Sells
About CALA
Calithera Biosciences, Inc., a clinical-stage bio-pharmaceutical company, focuses on the discovery and development of small molecule compounds for tumor metabolism and tumor immunology targets for the treatment of cancer in the United States. The company offers INCB001158, an orally bioavailable arginase inhibitor of arginase that is in Phase 1/2 clinical trial for the treatment of hematology and oncology. It is developing CB-280, an oral arginase inhibitor that has completed Phase 1b clinical trial for the treatment of cystic fibrosis and chronic airway infection; and ATG-037, an orally-bioavailable small molecule inhibitor of CD73, as well as CB-668, an orally administered inhibitor of the enzyme IL4I1. The company has a license agreement with Mars, Inc. to develop and commercialize Symbioscience's portfolio of arginase inhibitors for use in human healthcare. It also has clinical trial collaboration with Pfizer to evaluate Pfizer's PARP inhibitor talazoparib and CDK4/6 inhibitor palbociclib, each in combination with telaglenasta. In addition, the company has a collaboration and license agreement with Incyte Corporation for the research, development, and commercialization of INCB001158, a small molecule arginase inhibitor for the treatment of hematology and oncology; and a license agreement with Antengene Corporation Ltd. for the development and commercialization of CB-708. Calithera Biosciences, Inc. was incorporated in 2010 and is headquartered in South San Francisco, California.
Insider Transactions at CALA
Insider Transaction List
View allDate | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
---|---|---|---|---|---|
Jan 27
2023
|
Deepika Pakianathan Director |
SELL
Open market or private sale
|
Indirect |
121,333
-100.0%
|
$0
$0.39 P/Share
|
Jan 23
2023
|
Christopher Molineaux SR. VP, DEVELOPMENT |
SELL
Payment of exercise price or tax liability
|
Indirect |
217
-0.77%
|
$0
$0.45 P/Share
|
Jan 23
2023
|
Stephanie Wong Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
317
-4.8%
|
$0
$0.45 P/Share
|
Jan 23
2023
|
Susan Molineaux PRESIDENT & CEO |
SELL
Payment of exercise price or tax liability
|
Indirect |
526
-1.85%
|
$0
$0.45 P/Share
|
Jan 23
2023
|
Emil Kuriakose CHIEF MEDICAL OFFICER |
SELL
Payment of exercise price or tax liability
|
Direct |
79
-2.18%
|
$0
$0.45 P/Share
|
Jan 23
2023
|
Eric Sjogren SR. VP, DRUG DISCOVERY |
SELL
Payment of exercise price or tax liability
|
Direct |
279
-3.19%
|
$0
$0.45 P/Share
|
Jan 21
2022
|
Emil Kuriakose CHIEF MEDICAL OFFICER |
SELL
Payment of exercise price or tax liability
|
Direct |
666
-0.98%
|
$0
$0.49 P/Share
|
Jan 21
2022
|
Eric Sjogren SR. VP, DRUG DISCOVERY |
SELL
Payment of exercise price or tax liability
|
Direct |
4,794
-2.71%
|
$0
$0.49 P/Share
|
Jan 21
2022
|
Stephanie Wong Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
5,586
-4.06%
|
$0
$0.49 P/Share
|
Jan 21
2022
|
Francesco Parlati SR. VP, RESEARCH |
SELL
Payment of exercise price or tax liability
|
Direct |
4,794
-3.29%
|
$0
$0.49 P/Share
|
Jan 04
2022
|
Stephanie Wong Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
18,077
-11.61%
|
$0
$0.66 P/Share
|
Jan 04
2022
|
Eric Sjogren SR. VP, DRUG DISCOVERY |
SELL
Payment of exercise price or tax liability
|
Direct |
18,077
-9.26%
|
$0
$0.66 P/Share
|
Jan 04
2022
|
Emil Kuriakose CHIEF MEDICAL OFFICER |
SELL
Payment of exercise price or tax liability
|
Direct |
3,855
-5.36%
|
$0
$0.66 P/Share
|
Jan 04
2022
|
Francesco Parlati SR. VP, RESEARCH |
SELL
Payment of exercise price or tax liability
|
Direct |
18,077
-11.03%
|
$0
$0.66 P/Share
|
Nov 11
2021
|
Keith Orford Director |
SELL
Open market or private sale
|
Direct |
48,190
-42.17%
|
$0
$0.88 P/Share
|
Nov 10
2021
|
Keith Orford Director |
SELL
Open market or private sale
|
Direct |
30,000
-20.79%
|
$0
$0.86 P/Share
|
Nov 10
2021
|
Christopher Molineaux SR. VP, DEVELOPMENT |
BUY
Open market or private purchase
|
Indirect |
100,000
+15.22%
|
$0
$0.85 P/Share
|
Nov 10
2021
|
Jonathan G Drachman Director |
BUY
Open market or private purchase
|
Direct |
200,000
+50.0%
|
$0
$0.86 P/Share
|
Nov 10
2021
|
Susan Molineaux PRESIDENT & CEO |
BUY
Open market or private purchase
|
Indirect |
100,000
+15.22%
|
$0
$0.85 P/Share
|
Nov 09
2021
|
Keith Orford Director |
SELL
Open market or private sale
|
Direct |
51,810
-26.42%
|
$0
$0.84 P/Share
|